Form D · Pharmaceuticals
Intec Pharma Ltd.
Jerusalem, L3 · CIK 0001638381
Offering snapshot reported May 19, 2020 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 4, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 19, 2020 | Initial | $5,000,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $350K
- Finders' fees
- $0
- Form D file number
- 021-367324
The warrants and shares underlying the warrants, the subject matter of this Form D, were issued in connection with an offering of (i)16,291,952 shares issued in a registered direct offering, and (ii)unregistered warrants to purchase up to 8,145,976 shares
H.C. Wainwright is also entitled to a management fee equal to 1.0% of the gross proceeds raised in this offering and a non-accountable expense reimbursement of $75,000.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed May 19, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| R. Michael Gendreau | Executive |
| William B. Hayes | Director |
| Hila W. Karah | Director |
| John W. Kozarich | Director |
| Walt A Linscott | Executive |
| Anthony J. Maddaluna | Director |
| Jeffrey A. Meckler | Director, Executive |
| Nadav Navon | Executive |
| Roger J. Pomerantz | Director |
| Nir Sassi | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
12 Hartom Street Har Hotzvim
Jerusalem, L3, 777512
Jerusalem, L3, 777512